Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;10(1):45–76. doi: 10.1111/j.1527-3458.2004.tb00003.x

Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature

Joris C Verster 1,✉, Edmund R Volkerts 1
PMCID: PMC6741717  PMID: 14978513

ABSTRACT

Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazolam has a fast onset of symptom relief (within the first week); it is unlikely to produce dependency or abuse. No tolerance to its therapeutic effect has been reported. At discontinuation of alprazolam treatment, withdrawal and rebound symptoms are common. Hence, alprazolam discontinuation must be tapered.

An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antidepressants (TCAs), such as imipramine. However, although alprazolam and imipramine are significantly more effective than placebo in the treatment of panic attacks, Selective Serotonin Reuptake Inhibitors (SSRIs) appear to be superior to either of the two drugs. Therefore, alprazolam is recommended as a second line treatment option, when SSRIs are not effective or well tolerated.

In addition to its therapeutic effects, alprazolam produces adverse effects, such as drowsiness and sedation. Since alprazolam is widely used, many clinical studies investigated its cognitive and psychomotor effects. It is evident from these studies that alprazolam may impair performance in a variety of skills in healthy volunteers as well as in patients. Since the majority of alprazolam users are outpatients, this behavioral impairment limits the safe use of alprazolam in patients routinely engaged in potentially dangerous daily activities, such as driving a car.

Keywords: Alprazolam, Benzodiazepines, Anxiety, Depression, Panic, Sedation

Full Text

The Full Text of this article is available as a PDF (176.5 KB).

REFERENCES

  • 1. Abernethy DR, Greenblatt DJ, Divoll M, Moschitto LJ, Harmatz JS, Shader RI. Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. Psychopharmacology 1983;80:275–278. [DOI] [PubMed] [Google Scholar]
  • 2. Abernethy DR, Greenblatt DJ, Morse DS, Shader RI. Interaction of propoxyphene with diazepam, alprazolam and lorazepam. Br J Clin Pharmacol 1985;19:51–57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Achmin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effects of venlafaxine on the pharmacokinetics of alprazolam. Psychopharmacol Bull 1998;34:211–219. [PubMed] [Google Scholar]
  • 4. Aden GC, Thein SG. Alprazolam compared to diazepam and placebo in the treatment of anxiety. J Clin Psychiatry 1980;41:245–248. [PubMed] [Google Scholar]
  • 5. Alexander PE. The need for extended‐release medications. Curr Ther Res 1995;56:940–946. [Google Scholar]
  • 6. Allen D, Curran HV, Lader M. The effects of repeated doses of clomipramine and alprazolam on physiological, psychomotor and cognitive functions in normal subjects. Eur J Clin Pharmacol 1991;40:355–362. [DOI] [PubMed] [Google Scholar]
  • 7. American Psychiatric Association (APA). Practical guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998;155:1–34. [PubMed] [Google Scholar]
  • 8. Anderson IM, Nutt DJ, Deakin FW. Evidence‐based guideline for treating depressive disorders with antidepressants: Arevision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 2000;14:3–20. [DOI] [PubMed] [Google Scholar]
  • 9. Ansseau M, Ansoms C, Beckers G, et al. Double‐blind clinical study comparing alprazolam and doxepin in primary unipolar depression. J Affect Disord 1984;7:287–296. [DOI] [PubMed] [Google Scholar]
  • 10. Aranko K, Mattila MJ, Bordignon D. Psychomotor effects of alprazolam and diazepam during acute and subacute treatment, and during the follow‐up phase. Acta Pharmacol Toxicol 1985;56:364–372. [DOI] [PubMed] [Google Scholar]
  • 11. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: Efficacy in short‐term treatment. Arch Gen Psychiatry 1988;45:413–422. [DOI] [PubMed] [Google Scholar]
  • 12. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H‐J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive‐compulsive and posttraumatic stress disorders. World Biol Psychiatry 2002;3:171–199. [DOI] [PubMed] [Google Scholar]
  • 13. Banerji JR, Brantingham P, McEwan GD, et al. A comparison of alprazolam with amitriptyline in the treatment of patients with neurotic or reactive depression. Irish J Med Sci 1989;158:110–113. [DOI] [PubMed] [Google Scholar]
  • 14. Barbee JG, Black FW, Kehoe CE, Todorov AA. A comparison of the single‐dose effects of alprazolam, buspirone, and placebo upon memory function. J Clin Psychopharmacol 1991;11:351–356. [PubMed] [Google Scholar]
  • 15. Barbee JG, Mancuso DM, Freed CR, Todorov AA. Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry 1992;149:506–510. [DOI] [PubMed] [Google Scholar]
  • 16. Barbone F, McMahon AD, Davey PG, et al. Association of road‐traffic accidents with benzodiazepine use. Lancet 1998;352:1331–1336. [DOI] [PubMed] [Google Scholar]
  • 17. van den Berg F, Tulen JHM, Boomsma F, Noten JBGM, Moleman P, Pepplinkhuizen L. Effects of alprazolam and lorazepam on catecholaminergic and cardiovascular activity during supine rest, mental load and orthostatic challenge. Psychopharmacology 1996;128:21–30. [DOI] [PubMed] [Google Scholar]
  • 18. Berger CO, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: A double‐blind, placebo‐controlled crossover study. Obstet Gynecol 1994;84:379–385. [PubMed] [Google Scholar]
  • 19. Bertolino A, Mastucci E, Porro V, et al. Etizolam in the treatment of generalized anxiety disorder: A controlled clinical trial. J Int Med Res 1989;17:455–460. [DOI] [PubMed] [Google Scholar]
  • 20. Bertz RJ, Kroboth PD, Kroboth FJ, et al. Alprazolam in young and elderly men: Sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther 1997;281:1317–1329. [PubMed] [Google Scholar]
  • 21. Blackwell B. Compliance. Psychother Psychosomatics 1992;58:161–169. [DOI] [PubMed] [Google Scholar]
  • 22. Block RI, Berchou R. Alprazolam and lorazepam effects on memory acquisition and retrieval processes. Pharmacol Biochem Behav 1984;20:233–241. [DOI] [PubMed] [Google Scholar]
  • 23. Blom MW, Bartel PR, de Sommers K, Van der Meyden CH, Becker PJ. The effects of alprazolam, quazepam and diazepam on saccadic eye movements, parameters of psychomotor function and the EEG. Fund Clin Pharmacol 1990;4:653–661. [DOI] [PubMed] [Google Scholar]
  • 24. Bond A, Silveira JC, Lader M. Effects of single doses of alprazolam and alcohol alone and in combination on psychological performance. Hum Psychopharmacol 1991;6:219–228. [Google Scholar]
  • 25. Bond AJ, Silveira JC, Lader MH. The effects of alprazolam alone and in combination with alcohol on central integrative activity. Eur J Clin Pharmacol 1992;42:495–498. [DOI] [PubMed] [Google Scholar]
  • 26. Bond AJ, Silveira JC. The combination of alprazolam and alcohol on behavioral aggression. J Stud Alcohol 1993;11(Suppl):30–39. [DOI] [PubMed] [Google Scholar]
  • 27. Bond AJ, Curran HV, Bruce MS, O'Sullivan G, Shine P. Behavioural aggression in panic disorders after 8 weeks'treatment with alprazolam. J Affect Disord 1995;35:117–123. [DOI] [PubMed] [Google Scholar]
  • 28. Bourin M, Colombel M, Guitton B. Alprazolam 0.125 mg twice a day improves aspects of psychometric performance in healthy volunteers. J Clin Psychopharmacol 1998;18:364–372. [DOI] [PubMed] [Google Scholar]
  • 29. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: Ameta‐analysis. Int Clin Psychopharmacol 1995;10:45–49. [DOI] [PubMed] [Google Scholar]
  • 30. Bramanti P, Ricci RM, Rifici C, et al. Etizolam: A controlled study versus alprazolam in the treatment of generalized anxiety disorder with minor associated depressive symptoms. Curr Ther Res 1990;48:369–377. [Google Scholar]
  • 31. Brand N, Jolles J. Information procesing in depression and anxiety. Psychol Med 1987;17:97–105. [DOI] [PubMed] [Google Scholar]
  • 32. Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990;51:236–238. [PubMed] [Google Scholar]
  • 33. Bruce TJ, Spiegel DA, Gregg SF, Nuzzarello A. Predictors of alprazolam discontinuation with and without cognitive behavior therapy in panic disorder. Am J Psychiatry 1995;152:1156–1160. [DOI] [PubMed] [Google Scholar]
  • 34. Bruce SE, Vasile RG, Goisman RM, et al. Are benzodiazepines still the medication of choice for patients with panic disorder with or without agoraphobia Am J psychiatry 2003;160:1402–1409. [DOI] [PubMed] [Google Scholar]
  • 35. Buch AB, van Harken DR, Seidehamel RJ, Barbhaiya RH. A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 1993;33:1104–1109. [DOI] [PubMed] [Google Scholar]
  • 36. Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: Ameta‐analysis of the association, its pattern, and specificity. Psychol Bull 1995;117:285–305. [DOI] [PubMed] [Google Scholar]
  • 37. Busto U, Kaplan HL, Zawertailo L, Sellers EM. Pharmacologic effects and abuse liability of bretazenil, diazepam, and alprazolam in humans. Clin Pharmacol Ther 1994;55:451–463. [DOI] [PubMed] [Google Scholar]
  • 38. Busto UE, Kaplan HL, Wright CE, et al. A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained‐release, bromazepam, and lorazepam. J Clin Psychopharmacol 2000;20:628–635. [DOI] [PubMed] [Google Scholar]
  • 39. Cassano GB, Toni C, Petracca A, et al. Adverse effects associated with the short‐term treatment of panic disorder with imipramine, alprazolam or placebo. Eur Neuropsychopharmacol 1994;4:47–53. [DOI] [PubMed] [Google Scholar]
  • 40. Castillo A, Sotillo C, Mariategui J. Alprazolam compared to clobazam and placebo in anxious outpatients. Neuropsychobiology 1987;18:189–194. [DOI] [PubMed] [Google Scholar]
  • 41. Češková E, Švestka K, Náhunek K, Obrovská V. Double blind comparison of alprazolam with dosulepine in endogenous depression. Activ Nerv Super 1989;31:290–291. [PubMed] [Google Scholar]
  • 42. Charney DS, Woods SW, Goodman WK, et al. Drug treatment of panic disorder: The comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986;47:580–586. [PubMed] [Google Scholar]
  • 43. Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: A comparison of alprazolam and lorazepam. J Clin Psychiatry 1989;50:418–423. [PubMed] [Google Scholar]
  • 44. Christensen DB, Benfield WR. Alprazolam as an alternative to low‐dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998;46:620–625. [DOI] [PubMed] [Google Scholar]
  • 45. Ciraulo DA, Antal EJ, Smith RB, et al. The relationship of alprazolam dose to steady‐state plasma concentrations. J Clin Psychopharmacol 1990;10:27–32. [DOI] [PubMed] [Google Scholar]
  • 46. Ciraulo DA, Barnhill JG, Ciraulo AM, et al. Alternations in pharmacodynamics of anxiolytics in abstinent alcoholic men: Subjective reponses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. J Clin Psychopharmacol 1997;37:64–73. [DOI] [PubMed] [Google Scholar]
  • 47. Ciraulo DA, Knapp CM, LoCastro J, Greenblatt DJ, Shader RI. A benzodiazepine mood effect scale: Reliability and validity determined for alcohol‐dependent subjects and adults with a parental history of alcoholism. Am J Drug Alcohol Abuse 2001;27:339–347. [DOI] [PubMed] [Google Scholar]
  • 48. Clark DB, Taylor CB, Roth WT, et al. Surreptitious drug use by patients in a panic disorder study. Am J Psychiatry 1990;147:507–509. [DOI] [PubMed] [Google Scholar]
  • 49. Cohn JB. Multicenter double‐blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients. J Clin Psychiatry 1981;42:347–351. [PubMed] [Google Scholar]
  • 50. Cohn JB, Wilcox CS. Long‐term comparison of alprazolam, lorazepam and placebo in patients with an anxiety disorder. Pharmacotherapy 1984;4:93–98. [DOI] [PubMed] [Google Scholar]
  • 51. Cohn JB, Wilcox CS. Low‐sedation potential of buspirone compared with alprazolam and lorazepam in the treatment of anxious patients: A double‐blind study. J Clin Psychiatry 1986;47:409–412. [PubMed] [Google Scholar]
  • 52. Coldwell SE, Milgrom P, Getz T, Ramsay DS. Amnestic and anxiolytic effects of alprazolam in oral surgery patients. J Oral Maxillofac Surg 1997;55:1061–1070. [DOI] [PubMed] [Google Scholar]
  • 53. Cox BJ, Endler N, Lee PS, Swinson RP. A meta‐analysis of treatments for panic disorder with agoraphobia: Imipramine, alprazolam and in vivo exposure. J Behav Ther Exp Psychiatry 1992;23:175–182. [DOI] [PubMed] [Google Scholar]
  • 54. Crombez G, Kupers R, Adriaensen H. The effects of a single oral dose of lorazepam and alprazolam on reaction times in young healthy volunteers. Acta Anaesthesiol Belg 1991;42:79–84. [PubMed] [Google Scholar]
  • 55. Cross‐National Collaborative Panic Study , Second Phase Investigators. Drug treatment of panic disorder: Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 1992;160:191–202. [DOI] [PubMed] [Google Scholar]
  • 56. Curran HV. Benzodiazepines, memory and mood: Areview. Psychopharmacology 1991;105:1–8. [DOI] [PubMed] [Google Scholar]
  • 57. Curran HV, Bond A, O'Sullivan G, et al. Memory functions, alprazolam and exposure therapy: A controlled longitudinal study of agoraphobia with panic disorder. Psychol Medicine 1994;24:969–976. [DOI] [PubMed] [Google Scholar]
  • 58. Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB. Maintenance drug therapy of panic disorder. J Psychiat Res 1993;27(Suppl 1):127–142. [DOI] [PubMed] [Google Scholar]
  • 59. Dämgen K, Lüddens H. Zaleplon displays a selectivity to recombinant GABAA receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci Res Commun 1999;25:139–148. [Google Scholar]
  • 60. Danjou P, Warot D, Hergueta T, Lacomblez L, Bouhours P, Puech AJ. Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: Some trait anxiety‐independent responses. Int Clin Psychopharmacol 1992;7:73–79. [PubMed] [Google Scholar]
  • 61. Davison K, Farquharson RG, Kahn MC, et al. A double‐blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out‐patients. Psychopharmacology 1983;80:308–310. [DOI] [PubMed] [Google Scholar]
  • 62. Davison K, Farquharson RG, Kahn MC, et al. A double‐blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out‐patients. Br J Clin Pharmacol 1985;19(Suppl 1):37S–43S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Dehlin O, Kullingsjö H, Lidén A, Agrell B, Moser G, Olsen I. Pharmacokinetics of alprazolam in geriatric patients with neurotic depression. Pharmacol Toxicol 1991;68:121–124. [DOI] [PubMed] [Google Scholar]
  • 64. Diegoli MSC, da Fonseca AM, Diegoli CA, Pinotti JA. A double‐blind trial of four medications to treat severe premenstrual syndrome. Int J Gynecol Obstet 1998;62:63–67. [DOI] [PubMed] [Google Scholar]
  • 65. Doble A. New insights into the mechanisms of action hypnotics. J Psychopharmacol 1999;13(Suppl4): S11–S20. [DOI] [PubMed] [Google Scholar]
  • 66. Draper RJ, Daly I. Alprazolam and amitriptyline: A double blind comparison of anxiolytic and anti‐depressant activity. Irish Med J 1983;76:453–456. [PubMed] [Google Scholar]
  • 67. Dratcu L, Bond A. Panic patients in the non‐panic state: Physiological and cognitive dysfunction. Eur Psychiatry 1998;3:18–25. [DOI] [PubMed] [Google Scholar]
  • 68. Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effects of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. J Clin Psychiatry 1986;47:458–460. [PubMed] [Google Scholar]
  • 69. DuPont RL, Swinson RP, Ballenger JC, et al. Discontinuation of alprazolam after long‐term treatment of panic‐related disorders. J Clin Psychopharmacol 1992;12:352–354. [PubMed] [Google Scholar]
  • 70. Edwards JG, Inman WHW, Pearce GL, Rawson NSB. Prescription‐event monitoring of 10895 patients treated with alprazolam. Br J Psychiatry 1991;158:387–392. [DOI] [PubMed] [Google Scholar]
  • 71. Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984;4:125–129. [PubMed] [Google Scholar]
  • 72. Ellinwood EH, Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 1985;86:392–399. [DOI] [PubMed] [Google Scholar]
  • 73. Ellinwood EH, Nikaido AM, Heatherly DG, Bjornsson TD. Benzodiazepine pharmacodynamics: Evidence for biophase rate limiting mechanisms. Psychopharmacology 1987;91:168–174. [DOI] [PubMed] [Google Scholar]
  • 74. Ellinwood EH, Nikaido AM, Gupta SK, Heatherly DG, Hege S. Comparison of the relationship between structure and CNS effects for lorazepam, clonazepam and alprazolam. J Psychopharmacol 1993;7:24–32. [DOI] [PubMed] [Google Scholar]
  • 75. Enkelman R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991;105:428–432. [DOI] [PubMed] [Google Scholar]
  • 76. Eriksson B, Nagy A, Starmark J‐E, Thelander U. Alprazolam compared to amitriptyline in the treatment of major depression. Acta Psychiatr Scand 1987;75:656–663. [DOI] [PubMed] [Google Scholar]
  • 77. Evans SM, Troisi JR, Griffiths RR. Tandospirone and alprazolam: Comparison of behavioral effects and abuse liability in humans. J Pharmacol Exp Ther 1994;271:683–694. [PubMed] [Google Scholar]
  • 78. Evans SM, Foltin RW, Levin FR, Fischman MW. Behavioral and subjective effects of DN‐2327 (pazinaclone) and alprazolam in normal volunteers. Behav Pharmacol 1995;6:176–186. [PubMed] [Google Scholar]
  • 79. Evans SM, Haney M, Levin FR, Foltin RW, Fischman MW. Mood and performance changes in women with premenstrual dysphoric disorder: Acute effects of alprazolam. Neuropsychopharmacology 1998;19:499–516. [DOI] [PubMed] [Google Scholar]
  • 80. Evans SM, Foltin RW, Fischman MW. Food “cravings” and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999;32:331–349. [DOI] [PubMed] [Google Scholar]
  • 81. Evans SM, Levin FR, Fischman MW. Increased sensitivity to alprazolam in females with a paternal history of alcoholism. Psychopharmacology 2000;150:150–162. [DOI] [PubMed] [Google Scholar]
  • 82. Evans SM, Levin FR. The effects of alprazolam and buspirone in light and moderate female social drinkers. Behav Pharmacol 2002;13:427–439. [DOI] [PubMed] [Google Scholar]
  • 83. Fabre LF, McLendon D. Alprazolam efficacy in anxiety. Clin Pharmacol Ther 1979;25:233. [Google Scholar]
  • 84. Farbe LF, McLendon DM. A double‐blind study comparing the efficacy and safety of alprazolam with imipramine and placebo in primary depression. Curr Ther Res 1980;27:474–482. [Google Scholar]
  • 85. Fawcett J, Kravitz HM, Howard HM, Jeffriess H. Alprazolam: An antidepressant? Alprazolam, desipramine, and an alprazolam‐desipramine combination in the treatment of adult depressed outpatients. J Clin Psychopharmacol 1987;7:295–310. [PubMed] [Google Scholar]
  • 86. Feighner JP, Aden GC, Farbe LF, Rickels K, Smith WT. Comparison of alprazolam, imipramine, and placebo in the treatment of depression. JAMA 1983;249:3057–3064. [PubMed] [Google Scholar]
  • 87. Feighner JP, Meredith CH, Frost NR, Chammas S, Hendrickson G. A double‐blind comparison of alprazolam vs. imipramine and placebo in the treatment of major depressive disorder. Acta Psychiatr Scand 1983;68:223–233. [DOI] [PubMed] [Google Scholar]
  • 88. Ferguson HB, Simeon JG. Evaluating drug effects on children's cognitive functioning. Prog Neuropsycho-pharmacol Biol Psychiatry 1984;8:683–686. [DOI] [PubMed] [Google Scholar]
  • 89. Fernandez‐Guardiola A, Jurado JL, Aguilar‐Jimenez E. Evaluation of the attention and sleepiness states by means of a psychophysiological test of reaction time and time estimate in man: Effects of psychotropic drugs. Curr Ther Res 1984;35:1000–1009. [Google Scholar]
  • 90. Fleishaker JC, Phillips JP, Eller MG, Smith RB. Pharmacokinetics and pharmacodynamics of alprazolam following single and multiple oral doses of a sustained‐release formulation. J Clin Pharmacol 1989;29:543–549. [DOI] [PubMed] [Google Scholar]
  • 91. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35–39. [DOI] [PubMed] [Google Scholar]
  • 92. Fleishaker JC, Garzone PD, Chambers JH, Sirocco K, Weingartner H. Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Psychopharmacology 1995;120:169–176. [DOI] [PubMed] [Google Scholar]
  • 93. Freeman EW, Rickels K. Characteristics of placebo responses in medical treatment of premenstrual syndrome. Am J Psychiatry 1999;156:1403–1408. [DOI] [PubMed] [Google Scholar]
  • 94. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double‐blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51–57. [PubMed] [Google Scholar]
  • 95. Friedman MJ, Stolk JM, Harris PQ, et al. Serum dopamine‐β‐hydroxylase activity in depression and anxiety. Biol Psychiatry 1984;19:557–570. [PubMed] [Google Scholar]
  • 96. Fujita M, Woods SW, Verhoef NPLG, et al. Changes of benzodiazepine receptors during chronic benzodiaz‐epine administration in humans. Eur J Pharmacol 1999;368:161–172. [DOI] [PubMed] [Google Scholar]
  • 97. Furukori H, Otani K, Yasui N, et al. Effect of carbamazepine on the single oral dose pharmacokinetics of alprazolam. Neuropsychopharmacology 1998;18:364–369. [DOI] [PubMed] [Google Scholar]
  • 98. Gaillard AWK. The evaluation of drug effects in laboratory tasks In: Hindmarch I, Aufdembrinke B, Ott H, Eds. Psychopharmacology and Reaction Time. New York : Wiley Medical Publication, 1988. [Google Scholar]
  • 99. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive‐behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991;48:938–945. [DOI] [PubMed] [Google Scholar]
  • 100. Ghoneim MM, Mewaldt SP. Benzodiazepines and human memory: A review. Anesthesiology 1990;72:926–938. [PubMed] [Google Scholar]
  • 101. Gladsjo JA, Rapaport MH, McKinney R, et al. A neuropsychological study of panic disorder: Negative findings. J Affect Disord 1998;49:123–131. [DOI] [PubMed] [Google Scholar]
  • 102. Gladsjo JA, Rapaport MH, McKinney R, et al. Absence of neuropsychologic deficits in patients receiving long‐term treatment with alprazolam‐XR for panic disorder. J Clin Psychopharmacol 2001;21:131–138. [DOI] [PubMed] [Google Scholar]
  • 103. Goldberg SC, Ettigi P, Schulz PM, Hamer RM, Hayes PE, Friedel RO. Alprazolam versus imipramine in depressed out‐patients with neurovegetative signs. J Affect Disord 1986;11:139–145. [DOI] [PubMed] [Google Scholar]
  • 104. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Alprazolam kinetics in the elderly. Arch Gen Psychiatry 1983;40:287–290. [DOI] [PubMed] [Google Scholar]
  • 105. Greenblatt DJ, Harmatz JS, Dorsey C, Shader RI. Comparative single‐dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. Clin Pharmacol Ther 1988;44:326–334. [DOI] [PubMed] [Google Scholar]
  • 106. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Clin Pharmacokinet 1991;21:165–177. [DOI] [PubMed] [Google Scholar]
  • 107. Greenblatt DJ, Preskorn SH, Cotreau MM, Holst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479–486. [DOI] [PubMed] [Google Scholar]
  • 108. Greenblatt DJ, Wright E. Clinical pharmacokinetics of alprazolam. Therapeutic implications. Clin Pharmacokinet 1993;24:453–471. [DOI] [PubMed] [Google Scholar]
  • 109. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: Clinical implications. J Clin Psychiatry 1993;54(Suppl 10):4–11. [PubMed] [Google Scholar]
  • 110. Greenblatt DJ, Harmatz JS, Shader RI. Plasma alprazolam administrations. Relation to efficacy and side effects in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:715–722. [DOI] [PubMed] [Google Scholar]
  • 111. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther 1998;64:237–247. [DOI] [PubMed] [Google Scholar]
  • 112. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines. III A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15:399–408. [DOI] [PubMed] [Google Scholar]
  • 113. Gunal DI, Afsar N, Bekiroglu N, Aktan S. New alternative agents in essential tremor therapy: Double‐blind placebo‐controlled study of alprazolam and acetazolamide. Neurol Sci 2000;21:315–317. [DOI] [PubMed] [Google Scholar]
  • 114. Haney M, Foltin RW, Fischman MW. Behavioral contingencies modulate alprazolam self‐administration by humans. Behav Pharmacol 1997;8:82–90. [PubMed] [Google Scholar]
  • 115. Harrison WM, Endicott J, Nee J. Treatment of dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry 1990;47:270–275. [DOI] [PubMed] [Google Scholar]
  • 116. Hart RP, Colenda CC, Hamer RM. Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects. Am J Psychiatry 1991;148:73–77. [DOI] [PubMed] [Google Scholar]
  • 117. Hayashi R. Correlation between coefficient of variation of choice reaction time and components of event‐related potentials (P300): Effect of a benzodiazepine. J Neurol Sci 2000;178:52–56. [DOI] [PubMed] [Google Scholar]
  • 118. Hayoun H, Hirigoyen M‐F, Prigent Y, et al. Double‐blind, comparative, multicenter study of two benzodiazepines in 117 outpatients: Alprazolam versus clobazam. Psychiat Psychobiol 1987;2:202–213. [Google Scholar]
  • 119. Hecquet S, Puech AJ, Lecrubier Y. Double‐blind study, alprazolam versus lorazepam in ambulatory anxious patients. Therapie 1984;39:253–261. [PubMed] [Google Scholar]
  • 120. Hindmarch I. Measuring the side‐effects of psychoactive drugs: A pharmacodynamic profile of alprazolam. Alcohol Alcoholism 1983;18:361–367. [Google Scholar]
  • 121. Hoehn‐Saric R, McLoad DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293–301. [PubMed] [Google Scholar]
  • 122. Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991;9:1004–1011. [DOI] [PubMed] [Google Scholar]
  • 123. Hossain M, Wright E, Baweja R, Ludden T, Miller R. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. PharmacRes 1997;14:309–315. [DOI] [PubMed] [Google Scholar]
  • 124. Hubain PP, Castro P, Mesters P, De Maertelaer V, Mendlewicz J. Alprazolam and amitriptyline in the treatment of major depresssive disorder: A double‐blind clinical and sleep EEG study. J Affect Disord 1990;18:67–73. [DOI] [PubMed] [Google Scholar]
  • 125. Huynh L, Fields S. Alprazolam for tinnitus. Ann Pharmacother 1995;29:311–312. [DOI] [PubMed] [Google Scholar]
  • 126. Imlah NW. An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression. Br J Psychiatry 1985;146:515–519. [DOI] [PubMed] [Google Scholar]
  • 127. Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002;53:39–49. [DOI] [PubMed] [Google Scholar]
  • 128. Johnson RM, Brummett R, Schleuning A. Use of alprazolam for relief of tinnitus. A double‐blind study. Arch Otolaryngol Head Neck Surg 1993;119:842–845. [DOI] [PubMed] [Google Scholar]
  • 129. Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: A review of the literature. J Clin Psychiatry 1993;54 (Suppl 10):25–45. [PubMed] [Google Scholar]
  • 130. Jonas JM, Hearron AE. Alprazolam and suicidal ideation: A meta‐analysis of controlled trials in the treatment of depression. J Clin Psychopharmacol 1996;16:208–211. [DOI] [PubMed] [Google Scholar]
  • 131. Juhl RP, van Thiel DH, Dittert LW, Smith RB. Alprazolam pharmacokinetics in alcohol liver disease. J Clin Pharmacol 1984;24:113–119. [DOI] [PubMed] [Google Scholar]
  • 132. Jurado JL, Fernández‐Mas R, Fernández‐Guardiola A. Effects of 1 week administration of two benzodiazepines on the sleep and early daytime performance of normal subjects. Psychopharmacology 1989;99:91–93. [DOI] [PubMed] [Google Scholar]
  • 133. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Single‐dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. J Clin Pharmacol 1997;38:14–21. [DOI] [PubMed] [Google Scholar]
  • 134. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RI. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. J Clin Psychopharmacol 2000;20:338–346. [DOI] [PubMed] [Google Scholar]
  • 135. Katschnig H, Amering M, Stolk JM, et al. Long‐term follow‐up after a drug trial for panic disorder. Br J Psychiatry 1995;167:487–494. [DOI] [PubMed] [Google Scholar]
  • 136. Katschnig H, Amerig M, Stolk JM, Ballenger JC. Predictors of quality of life in a long‐term followup study in panic disorder patients after a clinical drug trial. Psychopharmacol Bull 1996;32:149–155. [PubMed] [Google Scholar]
  • 137. Kelly TH, Foltin RW, Serpick E, Fischman MW. Behavioral effects of alprazolam in humans. Behav Pharmacol 1997;8:47–57. [PubMed] [Google Scholar]
  • 138. Kiliç C, Curran HV, Noshirvani H, Marks IM, Başoǧlu M. Long‐term effects of alprazolam on memory: A 3.5 year follow‐up of agoraphobia/panic patients. Psychol Med 1999;29:225–31. [DOI] [PubMed] [Google Scholar]
  • 139. Kindermann SS, Brown GG. Depression and memory in the elderly: A meta‐analysis. J Clin Exp Neuropsychol 1997;19:625–642. [DOI] [PubMed] [Google Scholar]
  • 140. Kirkwood C, Moore A, Hayes P, DeVane CL, Pelonero A. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 1991;50:404–409. [DOI] [PubMed] [Google Scholar]
  • 141. Kizilbash AH, Vanderploeg RD, Curtiss G. The effects of depression and anxiety on memory performance. Arch Clin Neuropsychol 2002;17:57–67. [PubMed] [Google Scholar]
  • 142. Klerman GL. Overview of the cross‐national collaborative panic study. Arch Gen Psychiatry 1988;45:407–412. [DOI] [PubMed] [Google Scholar]
  • 143. Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavioral therapy in treatment of panic disorder. J Consult Clin Psychol 1990;58:77–84. [DOI] [PubMed] [Google Scholar]
  • 144. Koelega HS. Benzodiazepines and vigilance performance: A review. Psychopharmacology 1989;98:145–156. [DOI] [PubMed] [Google Scholar]
  • 145. Kolin IS, Linet OI. Double‐blind comparison of alprazolam and diazepam for subchronic withdrawal from alcohol. J Clin Psychiatry 1981;42:169–173. [PubMed] [Google Scholar]
  • 146. Korzekwa MI, Steiner M. Assessment and treatment of premenstrual syndromes. Prim Care Update Obstet Gynecol 1999;6:153–162. [Google Scholar]
  • 147. Kožená L, Frantik E, Horváth M. Vigilance impairment after a single dose of benzodiazepines. Psychopharmacology 1995;119:39–46. [DOI] [PubMed] [Google Scholar]
  • 148. Kožená L, Frantik E, Horváth M. Pharmacologically induced decrease in vigilance measured by two different psychological methods. Homeostasis 1997;38:64–65. [Google Scholar]
  • 149. Kravitz HM, Fawcett J, Newman AJ. Alprazolam and depression: A review of risks and benefits. J Clin Psychiatry 1993;54(Suppl 10):78–84. [PubMed] [Google Scholar]
  • 150. Kristjánsson F. Disposition of alprazolam in human volunteers. Differences between genders. Acta Pharm Nord 1991;3:249–250. [PubMed] [Google Scholar]
  • 151. Kroboth PD, Smith RB, Stoehr GP, Juhl RP. Pharmacodynamic evaluation of the benzodiazepine‐oral contraceptive interaction. Clin Pharmacol Ther 1985;38:525–532. [DOI] [PubMed] [Google Scholar]
  • 152. Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: Psychomotor and EEG effects. Clin Pharmacol Ther 1988;43:270–277. [DOI] [PubMed] [Google Scholar]
  • 153. Kroboth PD, McAuley JW, Smith RB. Alprazolam in the elderly: Pharmacokinetics and pharmacodynamics during multiple dosing. Psychopharmacology 1990;100:477–484. [DOI] [PubMed] [Google Scholar]
  • 154. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines. I. Pharmacodynamic assessment. J Clin Psychopharmacol 1995;15:306–319. [DOI] [PubMed] [Google Scholar]
  • 155. Kroboth PD, Folan MM, Bauer KS, Tullock W, Wright CE, Sweeney JA. Do alprazolam‐induced changes in saccadic eye movement and psychomotor function follow the same time course. J Clin Pharmacol 1998;38:337–346. [DOI] [PubMed] [Google Scholar]
  • 156. Kumar R, Mac DS, Gabrielli WF, Goodwin DW. Anxiolytics and memory: A comparison of lorazepam and alprazolam. J Clin Psychiatry 1987;48:158–160. [PubMed] [Google Scholar]
  • 157. Laakman G, Faltermaier‐Temizel M, Bossert‐Zaudig S, Baghai T, Lorkowski G. Treatment of depressive outpatients with lorazepam, alprazolam, amitriptyline and placebo. Psychopharmacology 1995;120:109–115. [DOI] [PubMed] [Google Scholar]
  • 158. van Laar MW, Volkerts ER, van Willigenburg APP. Therapeutic effects and effects on actual driving performance on chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 1992;12:86–95. [PubMed] [Google Scholar]
  • 159. Lappiere YD, Browne M, Oyewumi K, Sarantidis D. Alprazolam and amitriptyline in the treatment of moderate depression. Int Clin Psychopharmacol 1994;9:41–45. [DOI] [PubMed] [Google Scholar]
  • 160. Lasher TA, Fleishaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991;104:323–327. [DOI] [PubMed] [Google Scholar]
  • 161. Lenox RH, Shipley JE, Peyser JM, Williams JM, Weaver LA. Double‐blind comparison of alprazolam versus imipramine in the inpatient treatment of major depressive illness. Psychopharmacol Bull 1984;20:79–82. [PubMed] [Google Scholar]
  • 162. Leon CA, DeArango MV, Arevallo W, et al. On treatment of panic disorder in Cali, Columbia: A comparison between alprazolam, and imipramine‐administered samples, and a placebo‐administered control group. Acta Psiquiatr PsicolAm Lat 1990;36:59–72. [PubMed] [Google Scholar]
  • 163. Lepola U, Heikkinen H, Rimon R, Riekkinen P. Clinical evaluation of alprazolam in patients with panic disorder: A double‐blind comparison with imipramine. Hum Psychopharmacol 1990;5:159–164. [Google Scholar]
  • 164. Lepola UM, Rimon RH, Riekkinen PJ. Three‐year follow‐up of patients with panic disorder after shortterm treatment with alprazolam and imipramine. Int Clin Psychopharmacol 1993;8:115–118. [DOI] [PubMed] [Google Scholar]
  • 165. Lesser IM, Rubin RT, Pecknold JC, et al. Secondary depression in panic disorder and agoraphobia: Frequency, severity, and response to treatment. Arch Gen Psychiatry 1988;45:437–443. [DOI] [PubMed] [Google Scholar]
  • 166. Lesser IM, Lydiard RB, Antal E, Rubin RT, Ballenger JC, DuPont R. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 1992;149:1556–1562. [DOI] [PubMed] [Google Scholar]
  • 167. Linnoila M, Stapleton JM, Lister R, et al. Effects of single doses of alprazolam and diazepam, alone and in combination with ethanol, on psychomotor and cognitive performance and on autonomic nervous system reactivity in healthy volunteers. Eur J Clin Pharmacol 1990;39:21–28. [DOI] [PubMed] [Google Scholar]
  • 168. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology 1986;88:426–433. [DOI] [PubMed] [Google Scholar]
  • 169. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed‐dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96–103. [PubMed] [Google Scholar]
  • 170. Lydiard RB, Ballenger JC, Rickels K. A double‐blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. J Clin Psychiatry 1997;58(Suppl):11–18. [PubMed] [Google Scholar]
  • 171. Maletzky BM. Anxiolytic efficacy of alprazolam compared to diazepam and placebo. J Int Med Res 1980;8:139–143. [DOI] [PubMed] [Google Scholar]
  • 172. Marks IM, De Albuqueque A, Cottraux J, et al. The “efficacy” of alprazolam in panic disorder and agoraphobia: Acritique of recent reports. Arch Gen Psychiatry 1989;46:668–672. [DOI] [PubMed] [Google Scholar]
  • 173. Marks IM, Swinson RP, Başoǧlu M, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Clin Psychiatry 1993;162:776–787. [DOI] [PubMed] [Google Scholar]
  • 174. Marks IM, Swinson RP, Başoǧlu M, et al. Reply to comment on the London/Toronto study. Br J Psychiatry 1993;162:790–794. [DOI] [PubMed] [Google Scholar]
  • 175. Marks IM, Başoǧlu M, Noshirvani H, Greist J, Swinson RP, O'Sullivan G. Drug treatment of panic disorder. Br J Psychiatry 1993;162:795–796. [DOI] [PubMed] [Google Scholar]
  • 176. McAuley JW, Friedman CI. Influence of endogenous progesterone on alprazolam pharmacodynamics. J Clin Psychopharmacol 1999;19:233–239. [DOI] [PubMed] [Google Scholar]
  • 177. McLendon DM, Fabre LF. A double‐blind comparison of the efficacy of alprazolam, chlordiazepoxide hydrochloride and placebo in the chronic withdrawal period from alcohol. Curr Ther Res 1980;28:447–455. [Google Scholar]
  • 178. McLoad DR, Hoehn‐Saric R, Zimmerli WD, et al. Treatment effects of alprazolam and imipramine: Physiological v subjective changes in patients with generalized anxiety disorder. Biol Psychiatry 1990;28:849–861. [DOI] [PubMed] [Google Scholar]
  • 179. Meco G, Capriani C, Bonifati U, et al. Etizolam: Anew therapeutic possibility in the treatment of panic disorder. Advances in Therapy 1989;6:196–206. [Google Scholar]
  • 180. Mendels J, Schless AP. Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients. J Clin Psychiatry 1986;47:357–361. [PubMed] [Google Scholar]
  • 181. Möller H‐J, Volz H‐P, Reimann IW, Stoll K‐D. Opipramol for the treatment of generalized anxiety disorder: A placebo‐controlled trial including an alprazolam‐treated group. J Clin Psychopharmacol 2001;21:59–65. [DOI] [PubMed] [Google Scholar]
  • 182. Mühlberg W, Rieck W, Arnold E, Ott G, Lungershausen E. Pharmacokinetics of alprazolam in elderly patients with multiple diseases. Arch Gerontol Geriatr 1997;25:91–100. [DOI] [PubMed] [Google Scholar]
  • 183. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 1995;57:356–366. [DOI] [PubMed] [Google Scholar]
  • 184. Mumford GK, Rush CR, Griffiths RR. Alprazolam and DN‐2327 (Pazinaclone) in humans: Psychomotor, memory, subjective, and reinforcing effects. Exp Clin Psychopharmacol 1995;3:39–48. [Google Scholar]
  • 185. Mumford GK, Rush CR, Griffiths RR. Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 1995;272:570–580. [PubMed] [Google Scholar]
  • 186. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propanolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989;9:22–27. [PubMed] [Google Scholar]
  • 187. Münte TF, Gehde E, Johannes S, Seewald M, Heinze H. Effects of alprazolam and bromazepam on visual search and verbal recognition memory in humans: A study with event‐related brain potentials. Neuropsychobiology 1996;34:49–56. [DOI] [PubMed] [Google Scholar]
  • 188. Nikaido AM, Ellinwood EH, Heatherly DG, Gupta SK. Age‐related increase in CNS sensitivity to benzodiazepines as assessed by task difficulty. Psychopharmacology 1990;100:90–97. [DOI] [PubMed] [Google Scholar]
  • 189. Norman TR, Burrows GD, McIntyre IM. Pharmacokinetic and pharmacodynamic effects of a single nocturnal dose of alprazolam. Int Clin Psychopharmacol 1990;5:111–117. [DOI] [PubMed] [Google Scholar]
  • 190. Noyes R, DuPont RL, Pecknold JC, et al. Alprazolam in panic disorder and agopraphobia: Patient acceptance, side effects, and safety. Arch Gen Psychiatry 1988;45:423–428. [DOI] [PubMed] [Google Scholar]
  • 191. Noyes R, Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am J Psychiatry 1991;148:517–523. [DOI] [PubMed] [Google Scholar]
  • 192. Noyes R, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996;57:349–355. [PubMed] [Google Scholar]
  • 193. O'Hanlon JF, Haak TW, Blaauw GJ, et al. Diazepam impairs lateral position control in highway driving. Science 1982;217:79–81. [DOI] [PubMed] [Google Scholar]
  • 194. Oo CY, Kuhn RJ, Wright CE, McNamara PJ. Pharmacokinetics in lactating women: Prediction of alprazolam transfer into milk. Br J Clin Pharmacol 1995;40:231–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195. O'Sullivan GH, Noshirvani H, Başoǧlu M, et al. Safety and side effects of alprazolam. Controlled study in agoraphobia with panic disorder. Br J phychiarty 1994;165:79–86. [DOI] [PubMed] [Google Scholar]
  • 196. Oswald LM, Roache JD, Rhoades HM. Predictors of individual differences in alprazolam self‐medication. Exp Clin Psychopharmacol 1999;7:379–390. [DOI] [PubMed] [Google Scholar]
  • 197. Otani K, Yasui N, Kaneko S, et al. Effects of genetically determined s‐mephentoin 4‐hydroxylation status and cigarette smoking on the single‐dose pharmacokinetics of oral alprazolam. Neuropsychopharmacology 1997;16:8–14. [DOI] [PubMed] [Google Scholar]
  • 198. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer‐Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: Efficacy of cognitive‐behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485–1490. [DOI] [PubMed] [Google Scholar]
  • 199. Overall JE, Donachie ND, Faillace LA. Implications of restrictive diagnosis for compliance to antidepressant drug therapy: Alprazolam versus imipramine. J Clin Psychiatry 1987;48:51–54. [PubMed] [Google Scholar]
  • 200. Pariante F, Cadeo S, Ecari U. Etizolam in the treatment of generalized anxiety disorder associated with depressive symptoms. Curr Med Res Opin 1989;11:543–549. [DOI] [PubMed] [Google Scholar]
  • 201. Pearlstein TP, Stone AB. Longterm fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994;55:332–335. [PubMed] [Google Scholar]
  • 202. Pecknold JC, Swinson RP. Taper withdrawal studies with alprazolam in patients with panic disorder and agoraphobia. Psychopharmacol Bull 1986;22:173–176. [PubMed] [Google Scholar]
  • 203. Pecknold JC, Swinson RP, Kuch K, Lewis CP. Alprazolam in panic disorder and agoraphobia: Discontinuation effects. Arch Gen Psychiatry 1988;45:429–436. [DOI] [PubMed] [Google Scholar]
  • 204. Petty F, Trivedi MH, Fulton M, Rush AJ. Benzodiazepines as antidepressants: Does GABA play a role in depression Biol Psychiatry 1995;38:578–591. [DOI] [PubMed] [Google Scholar]
  • 205. Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer‐Brody S, Rosenbaum JF. Long‐term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993;13:257–263. [PubMed] [Google Scholar]
  • 206. Pomara N, Tun H, DaSilva D, Hernando R, Deptula D, Greenblatt DJ. The acute and chronic performance effects of alprazolam and lorazepam in the elderly: Relationship to duration of treatment and self‐rated sedation. Psychopharmacol Bull 1998;34:139–153. [PubMed] [Google Scholar]
  • 207. Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1985;23:447–451. [PubMed] [Google Scholar]
  • 208. Pyke RE, Greenberg HS. Double‐blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989;9:15–21. [PubMed] [Google Scholar]
  • 209. Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ. A controlled study of alprazolam and propanolol in panic‐disordered and agoraphobic outpatients. J Clin Psychopharmacol 1991;11:344–350. [PubMed] [Google Scholar]
  • 210. Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JAE. A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients. Can J Psychiatry 1988;33:590–594. [DOI] [PubMed] [Google Scholar]
  • 211. Riba J, Rodriguez‐Fornells A, Urbano G, Morte A, Antonijoan R, Barbanoj MJ. Differential effects of alprazolam on the baseline and fear‐potentiated startle reflex in humans: A dose response study. Psychopharmacology 2001;157:358–367. [DOI] [PubMed] [Google Scholar]
  • 212. Rickels K, Cohen D, Csanalosi I, Harris H, Koepke H, Werblowsky J. Alprazolam and imipramine in depressed outpatients: A controlled study. Curr Ther Res 1982;32:157–164. [Google Scholar]
  • 213. Rickels K, Csanalosi I, Greisman P, et al. A controlled clinical trial of alprazolam for the treatment of anxiety. Am J Psychiatry 1983;140:82–85. [DOI] [PubMed] [Google Scholar]
  • 214. Rickels K, Schweizer E, Csanalosi I, Case W, Chung H. Long‐term treatment of anxiety and risks of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45:444–450. [DOI] [PubMed] [Google Scholar]
  • 215. Rickels K, Schweizer E, Weiss S, Zavodnick S. Maintenance drug treatment for panic disorder. II. Short‐and long‐term outcome after drug taper. Arch Gen Psychiatry 1993;50:61–68. [DOI] [PubMed] [Google Scholar]
  • 216. Rickels K, Schweizer E. Panic disorder: long‐term pharmacotherapy and discontinuation. J Clin Psychopharmacol 1998(Suppl 2):12S–18S. [DOI] [PubMed]
  • 217. Rickels K, Lucki I, Schweizer E, Garcia‐Espana F, Case WG. Psychomotor performance of long‐term benzodiazepine users before, during, and after benzodiazepine discontinuation. J Clin Psychopharmacol 1999;19:107–113. [DOI] [PubMed] [Google Scholar]
  • 218. Rimon R, Kultalahti E‐R, Kalli A, et al. Alprazolam and oxazepam in the treatment of anxious out‐patients with depressive symptoms: A double‐blind multicenter study. Pharmacopsychiatry 1991;24:81–84. [DOI] [PubMed] [Google Scholar]
  • 219. Rizley R, Kahn RJ, McNair DM, Frankenthaler BA. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull 1986;22:167–172. [PubMed] [Google Scholar]
  • 220. Rohling ML, Green P, Allen LM III, Iverson GL. Depressive symptoms and neurocognitive test scores in patients pasing symptom validity tests. Arch Clin Neuropsychol 2002;17:205–222. [PubMed] [Google Scholar]
  • 221. Romach MK, Busto UE, Sobell LC, Sobel MB, Somer GR, Sellers EM. Long‐term alprazolam use: Abuse, dependence or treatment Psychopharmacol Bull 1991;27:391–395. [PubMed] [Google Scholar]
  • 222. Romach MK, Somer GR, Sobell LC, Sobell MB, Kaplan HL, Sellers EM. Characteristics of long‐term alprazolam users in the community. J Clin Psychopharmacol 1992;12:316–321. [PubMed] [Google Scholar]
  • 223. Romach M, Busto U, Somer G, Kaplan HL, Sellers E. Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry 1995;152:1161–1167. [DOI] [PubMed] [Google Scholar]
  • 224. Romach MK, Kaplan HL, Busto UE, Somer G, Sellers EM. A controlled trial of ondansetron, a 5‐HT3 antagonist, in benzodiazepine discontinuation. J Clin Psychopharmacol 1998;18:121–131. [DOI] [PubMed] [Google Scholar]
  • 225. Roy‐Byrne P, Fleishaker J, Arnett C, et al. Effects of acute and chronic alprazolam treatment on cerebral blood flow, memory, sedation, and plasma catecholamines. Neuropsychopharmacology 1993;8:161–169. [DOI] [PubMed] [Google Scholar]
  • 226. Rudolph U, Crestani F, Möhler H. GABAA receptor subtypes: Dissecting their pharmacological functions. Trends Pharmacol Sci 2001;22:188–194. [DOI] [PubMed] [Google Scholar]
  • 227. Rush AJ, Erkman MK, Schlesser MA, et al. Alprazolam vs amitriptyline in depressions with reduced REM latencies. Arch Gen Psychiatry 1985;42:1154–1159. [DOI] [PubMed] [Google Scholar]
  • 228. Rush CR, Griffiths RR. Acute participant‐rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp Clin Psychopharmacol 1997;5:28–38. [DOI] [PubMed] [Google Scholar]
  • 229. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. Arthr Rheum 1991;34:552–560. [DOI] [PubMed] [Google Scholar]
  • 230. Saletu B, Grünberger J, Linzmayer L, Semlitsch HV, Anderer P, Chwatal K. Pharmacokinetic and‐dynamic studies with a new anxiolytic, suriclone, utilizing EEG mapping and psychometry. Br J Clin Pharmacol 1994;37:145–156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231. Sanger DJ, Benavides J, Perrault G, et al. Recent developments in the behavioral pharmacology of benzodiazepine (ω) receptors: Evidence for the functional significance of receptor subtypes. Neurosci Biobehav Rev 1994;18:355–372. [DOI] [PubMed] [Google Scholar]
  • 232. Scavone JM, Greenblatt DJ, Shader RI. Alprazolam kinetics following sublingual and oral administration. J Clin Psychopharmacol 1987;7:332–334. [PubMed] [Google Scholar]
  • 233. Scavone JM, Greenblatt DJ, Goddard JE, Friedman H, Harmatz JS, Shader RI. The pharmacokinetics and pharmacodynamics of sublingual and oral alprazolam in the post‐prandial state. Eur J Clin Pharmacol 1992;42:439–443. [DOI] [PubMed] [Google Scholar]
  • 234. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. A double‐blind, placebo‐controlled trial. Arch Gen Psychiatry 1993;50:467–473. [DOI] [PubMed] [Google Scholar]
  • 235. Schmith VD, Piraino, Smith , Kroboth PD. Alprazolam in end‐stage renal disease. I. Pharmacokinetics. J Clin Pharmacol 1991;31:571–579. [DOI] [PubMed] [Google Scholar]
  • 236. Schmith VD, Piraino B, Smith RB, Kroboth PD. Alprazolam in end‐stage renal disease. II. Pharmacodynamics. Clin Pharmacol Ther 1992;51:533–540. [DOI] [PubMed] [Google Scholar]
  • 237. Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990;23:90–93. [DOI] [PubMed] [Google Scholar]
  • 238. Schweizer E, Patterson W, Rickels K, Rosenthal M. Double‐blind, placebo‐controlled study of a once‐a‐day, sustained‐release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 1993;150:1210–1215. [DOI] [PubMed] [Google Scholar]
  • 239. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo‐controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51–60. [DOI] [PubMed] [Google Scholar]
  • 240. Seidel WF, Cohen L, Wilson L, Dement WC. Effects of alprazolam and diazepam on the daytime sleepiness of non‐anxious subjects. Psychopharmacology 1985;87:194–197. [DOI] [PubMed] [Google Scholar]
  • 241. Sellers EM, Ciraulo DA, DuPont RL, et al. Alprazolam and benzodiazepine dependence. J Clin Psychiatry 1993;54(Suppl 10):64–75. [PubMed] [Google Scholar]
  • 242. Semlitsch HV, Anderer P, Saletu B. Acute effects of the anxiolytics suriclone and alprazolam on cognitive information processing utilizing topographic mapping of event‐related brain potentials (P300) in healthy subjects. Eur J Clin Pharmacol 1995;49:183–191. [DOI] [PubMed] [Google Scholar]
  • 243. Sheehan DV, Coleman JH, Greenblatt DJ, et al. Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacol 1984;4:66–75. [DOI] [PubMed] [Google Scholar]
  • 244. Sheehan DV, Raj AB, Harnett‐Sheehan K, Soto S, Knapp E. The relative efficacy of high‐dose buspirone and alprazolam in the treatment of panic disorder: A double‐blind placebo‐controlled study. Acta Psychiatr Scand 1993;88:1–11. [DOI] [PubMed] [Google Scholar]
  • 245. Sheikh JI, Swales JI. Treatment of panic disorder in older adults: A pilot study comparison of alprazolam, imipramine and placebo. Int J Psychiatr Med 1999;29:107–117. [DOI] [PubMed] [Google Scholar]
  • 246. Shelton RC, Harvey DS, Stewart PM, Loosen PT. Alprazolam in panic disorder: A retrospective analysis. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:423–434. [DOI] [PubMed] [Google Scholar]
  • 247. Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992;31:29–33. [DOI] [PubMed] [Google Scholar]
  • 248. Simpson JJ, Davies WE. Recent advances in the pharmacological treatment of tinnitus. Trends Pharmacol Sci 1999;20:12–18. [DOI] [PubMed] [Google Scholar]
  • 249. Singh AN, Nair NPV, Suranyi‐Cadotte B, Schwartz G, Lizondo E. A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depression. Can J Psychiatry 1988;33:218–222. [DOI] [PubMed] [Google Scholar]
  • 250. Smith RB, Kroboth PD, Vanderlught JT, Philips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology 1984;84:452–456. [DOI] [PubMed] [Google Scholar]
  • 251. Smith RB, Gwilt PR, Wright CE. Single and multiple dose pharmacokinetics of oral alprazolam in healthy smoking and nonsmoking men. Clin Pharmacy 1983;2:139–143. [PubMed] [Google Scholar]
  • 252. Smith RB, Kroboth PD. Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 1987;93:105–112. [DOI] [PubMed] [Google Scholar]
  • 253. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: Results of a double‐blind, placebo‐controlled, randomized crossover clinical trial. Obstet Gynecol 1987;70:37–43. [PubMed] [Google Scholar]
  • 254. Spiegel DA, Roth SM, Weissman M, Lavori P, Gorman J, Ballenger J. Comment on the London/Toronto study of alprazolam and exposure in panic disorder with agoraphobia. Br J Psychiatry 1993;162:788–789. [DOI] [PubMed] [Google Scholar]
  • 255. Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol 1999;19:17S–22S. [DOI] [PubMed] [Google Scholar]
  • 256. Srisurapanont M, Boonyanaruthee V. Alprazolam and standard antidepressants in the treatment of depression: A meta‐analysis of the antidepressant effect. J Med Ass Thai 1997;80:183–188. [PubMed] [Google Scholar]
  • 257. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995;332:1529–1534. [DOI] [PubMed] [Google Scholar]
  • 258. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997;33:771–774. [PubMed] [Google Scholar]
  • 259. Streeter CC, Ciraulo DA, Harris GJ, et al. Functional magnetic resonance imaging of alprazolam‐induced changes in humans with familial alcoholism. Psychiatry Res Neuroimaging 1998;82:69–82. [DOI] [PubMed] [Google Scholar]
  • 260. Streufert S, Satish U, Pogash R, et al. Effects of alprazolam on complex human functioning. J Appl Soc Psychol 1996;26:1912–1930. [Google Scholar]
  • 261. Subhan Z, Harrison Ch, Hindmarch I. Alprazolam and lorazepam. Single and multiple‐dose effects on psychomotor skills and sleep. Eur J Clin Pharmacol 1986;29:709–712. [DOI] [PubMed] [Google Scholar]
  • 262. Sumner DD. Benzodiazepine‐induced persisting amnestic disorder: Are older adults at risk Arch Psychiat Nursing 1998;12:119–125. [DOI] [PubMed] [Google Scholar]
  • 263. Suzuki M, Uchiumi M, Murasaki M. A comparative study of the psychological effects of DN‐2327, a partial benzodiazepine agonist, and alprazolam. Psychopharmacology 1995;121:442–450. [DOI] [PubMed] [Google Scholar]
  • 264. Swann AC, Katz MM, Bowden CL, Berman NG, Stokes PE. Psychomotor performance and monoamine function in bipolar and unipolar affective disorders. Biol Psychiatry 1999;45:979–988. [DOI] [PubMed] [Google Scholar]
  • 265. Taylor CB, Hayward C, King R, et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: Results of a double‐blind, placebo‐controlled trial. J Clin Psychopharmacol 1990;10:112–118. [DOI] [PubMed] [Google Scholar]
  • 266. Tesar GE, Rosenbaum JF, Pollach MH, et al. Clonazepam versus alprazolam in the treatment of panic disorder: Interim analysis of data from a prospective, double‐blind, placebo‐controlled trial. J Clin Psychiatry 1987;48(Suppl 10):16–19. [PubMed] [Google Scholar]
  • 267. Tesar GE, Rosenbaum JF, Pollach MH, et al. Double‐blind, placebo‐controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69–76. [PubMed] [Google Scholar]
  • 268. Tollefson GD, Luxenberg M, Valentine R, Dunsmore G, Tolefson SL. An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. J Clin Psychiatry 1991;52:502–508. [PubMed] [Google Scholar]
  • 269. Torres‐Ruiz AT. A double‐blind study of alprazolam and lorazepam in the treatment of anxiety. J Clin Psychiatry 1983;44:60–62. [PubMed] [Google Scholar]
  • 270. Uhlenhuth EH, Matuzas W, Glass RM, Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989;17:261–270. [DOI] [PubMed] [Google Scholar]
  • 271. Uhlenhuth EH, Alexander PE, Dempsey GM, Jones W, Coleman BS, Swiontek AM. Medication side effects in anxious patients: Negative placebo responses J Affect Disord 1998;47:183–190. [DOI] [PubMed] [Google Scholar]
  • 272. Väissänen E, Jalkanen E. A double‐blind study of alprazolam and oxazepam in the treatment of anxiety. Acta Psychiatr Scand 1987;75:536–541. [DOI] [PubMed] [Google Scholar]
  • 273. Vermeeren A, Jackson JL, Muntjewerff ND, Quint PJ, Harrison EM, O'Hanlon JF. Comparison of acute alprazolam (0.25, 0.50 and 1.0 mg) effects versus those of lorazepam 2 mg and placebo on memory in healthy volunteers using laboratory and telephone tests. Psychopharmacology 1995;118:1–9. [DOI] [PubMed] [Google Scholar]
  • 274. Verster JC, Volkerts ER, Verbaten MN. Effects of alprazolam on driving ability, memory functioning and psychomotor performance: A randomized, placebo‐controlled study. Neuropsychopharmacology 2002;27:260–269. [DOI] [PubMed] [Google Scholar]
  • 275. Verster JC, Verbaten MN, Volkerts ER. Next‐day residual effects of sleeping medicine on driving ability: A review of the literature. In: Lader M, Pandi‐Perumal SR, Cardinali OP, Eds. Sleep and sleep disorders: A neuropsychopharmacological approach. Landes Bioscience, in press.
  • 276. Wald TG, Kathol RG, Noyes R, Carrol BT, Clamon GH. Rapid relief of anxiety in cancer patients with both alprazolam and placebo. Psychosomatics 1993;34:324–332. [DOI] [PubMed] [Google Scholar]
  • 277. Weissman MM, Prusoff B, Sholomskas AJ, Greenwald S. A double‐blind clinical trial of alprazolam, or placebo in the depressed elderly. J Clin Psychopharmacol 1992;12:175–182. [PubMed] [Google Scholar]
  • 278. Wilcox JA. An open comparison of diazepam and alprazolam. JPsychoact Drugs 1986;18:159–160. [DOI] [PubMed] [Google Scholar]
  • 279. Wilhelm FH, Roth WT. Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther 1997;35:831–841. [DOI] [PubMed] [Google Scholar]
  • 280. Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: Preliminary results. J Clin Psychopharmacol 1991;11:48–51. [PubMed] [Google Scholar]
  • 281. Wong SL, Locke C, Staser J, Granneman GR. Lack of multiple dosing effects of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology 1998;135:236–241. [DOI] [PubMed] [Google Scholar]
  • 282. Woodman CL, Noyes R, Ballenger JC, Lydiard RB, Sievers G, Mihalko D. Predictors of response to alprazolam and placebo in patients with panic disorder. J Affect Disord 1994;30:5–13. [DOI] [PubMed] [Google Scholar]
  • 283. Wright CE, Lasher Sisson T, Fleishaker JC, Antal EJ. Pharmacokinetics and psychomotor performance of alprazolam: Concentration‐effect relationship. J Clin Pharmacol 1997;37:321–329. [DOI] [PubMed] [Google Scholar]
  • 284. Yamadera H, Okawa M, Takahashi K. Open study of effects of alprazolam on seasonal affective disorder. Psychiatr Clin Neurosci 2001;55:27–30. [DOI] [PubMed] [Google Scholar]
  • 285. Yasui N, Otani K, Kaneko S, et al. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: In vitro evidence for the involvement of CYP3A4 in alprazolam metabolism. Clin Pharmacol Ther 1996;59:514–519. [DOI] [PubMed] [Google Scholar]
  • 286. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 1998;139:269–273. [DOI] [PubMed] [Google Scholar]
  • 287. Yasui N, Kondo T, Furukori H, et al. Effects of repeated ingestion of grapefruit juice on the single and multiple oral‐dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 2000;150:185–190. [DOI] [PubMed] [Google Scholar]
  • 288. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. JAMA 1997;278:983–988. [PubMed] [Google Scholar]
  • 289. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal sphase: A randomized, placebo‐controlled crossover trial. J Clin Psychiatry 1998;59:76–80. [DOI] [PubMed] [Google Scholar]
  • 290. Zamorski MA, Albucher RC. What to do when SSRIs fail: Eight strategies for optimizing treatment of panic disorder. Am Fam Physician 2002;66:1477–84. [PubMed] [Google Scholar]
  • 291. Zawertailo LA, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. J Clin Psychopharmacol 1995;15:117–124. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES